Bharat Immunologicals stock drops on Cabinet shutdown nod

Stock snapshot: price, change, and trading context

Bharat Immunologicals and Biologicals Corporation Ltd was trading at ₹15.00 in INR, with a reported move of -₹0.25 (-1.64%) on delayed data. The previous close cited for the same price point was ₹15.25. Another market data snapshot showed the stock at ₹15.02, down 0.6% from ₹15.11, with an intraday range of ₹15.25 to ₹14.95. These prints underline how closely the stock has been trading around the ₹15 level through September 2026.

The company is listed on the BSE, and the BSE scrip code referenced is 524663. Market data in the provided inputs also uses both BIBC and BIBCL as ticker references in different places, with $BIBC noted as a common social media shorthand. The reporting currency across the sources is INR.

The trigger: Cabinet clears a proposal to shut BIBCOL

According to sources cited in the provided text, the Union Cabinet, chaired by Prime Minister Narendra Modi, cleared a proposal to shut down Bharat Immunologicals Biologicals Corporation Limited (BIBCOL). The decision is significant because BIBCOL is described as a PSU vaccine and biologicals manufacturer.

The same source context says the company has faced severe operational, administrative, and financial issues. That framing matters for investors because a closure proposal can shift attention from routine operating updates to questions around continuity of operations, asset value, and any next procedural steps. The inputs do not provide details on timelines, employee measures, or the formal process beyond the Cabinet clearance noted by sources.

Operations and product mix: what BIBCOL makes

Bharat Immunologicals & Biologicals Corporation Limited is described as a biotechnology company engaged in the manufacture and sale of pharmaceutical products in India. Products mentioned include Oral Polio Vaccine (OPV), zinc tablets, diarrhea management kits, and BIB sweet tablets.

It is also described as a Central Public Sector Unit under the Department of Biotechnology, Ministry of Science and Technology. The company’s manufacturing unit is cited as being located in Bulandshahr district, Uttar Pradesh, with references to an OPV plant at Village Chola in Bulandshahr.

Key operational disruption: OPV production stopped in late 2022

A critical operational detail in the provided information is that BIBCOL’s primary manufacturing facility in Chola, Bulandshahr, stopped producing its core offering, the Oral Polio Vaccine (OPV), in late 2022. OPV is explicitly called the company’s “core offering” in the text.

That stoppage provides background for why a shutdown proposal has emerged in official decision-making. It also helps explain why investors may interpret the headline as more than a one-off administrative update, given that a core production line has been halted for an extended period.

Company profile and incorporation details

The company was incorporated in 1989 and is based in Bulandshahr (Bulandshahr district), India, according to the supplied company description. A separate company profile snippet lists the CEO as Dhananjay Tiwary and references the website bibcol.sciencecentral.in.

The same profile block mentions the fiscal year as April to March and provides an ISIN: INE994B01014.

Recent price points and returns cited in the data

Multiple dated snapshots were included in the text:

• As of Sep 17, 2026, the stock was cited at ₹15.00, with a previous close of ₹15.25.
• As of 16 Sep 2026, the share price was cited at ₹15.2, with an open at ₹15.1 and a prior close of ₹14.8.
• As of 10 Sep 2026, the share price was cited at ₹15.05.

The provided returns data says:

• Past 1 week: -2.02%
• Past 1 month: -8.68%

These figures, as presented, indicate recent weakness over the month even as the stock has remained near the mid-teens in absolute price.

Valuation and trading metrics highlighted

The inputs include several market metrics (as cited): P/E -3.72, P/B -2.67, EPS (TTM) ₹-4.18, ROE -22.95%, beta 0.84, outstanding shares 4.32 crore, face value ₹10, and book value ₹-7.54. A 52-week range is also provided in two variants: 52-week high ₹23.13 and low ₹14.1, and another range cited as ₹14.1 to ₹22.61.

While the dataset does not provide the underlying financial statements, these metrics show the market is pricing the company alongside negative profitability indicators (as reflected in the negative EPS and negative P/E in the quoted data).

Market capitalisation: different snapshots across dates

Market capitalisation figures vary across the snapshots provided:

• ₹86.49 crore (as of 03 Sep 2026) is cited alongside other trading metrics.
• ₹68.22 crore (as of 10 Sep 2026) is cited in an FAQ-style block.
• ₹67.14 crore (as of 15 Sep 2026) is cited with the ₹15.02 price snapshot.

Because these values come from different timestamps and data blocks, they should be read as separate point-in-time estimates rather than a single definitive figure.

Key facts table

Analysis: why the shutdown proposal matters for investors

The Cabinet clearance to shut down BIBCOL, as cited by sources, places the company’s future squarely in focus, especially against the backdrop of OPV production having stopped in late 2022. For a PSU manufacturer whose product mix explicitly includes OPV, the absence of production in the core line can reshape how investors interpret routine price moves and short-term volatility around ₹15.

The stock’s recent returns data in the inputs shows a negative trend over the past month (-8.68%), and the valuation metrics listed include a negative EPS and negative P/E. Together with reported operational disruption, these datapoints frame why policy-level decisions can become the dominant driver of sentiment in the near term.

What to watch next

The provided text does not include the next procedural steps, a closure timeline, or detailed disclosures from the company. Investors will likely watch for formal communication following the Cabinet clearance referenced by sources, and for any exchange filings on BSE linked to operational status.

Separately, the inputs show historical compliance and board meeting intimations under SEBI LODR in 2024, underscoring that future updates, if any, are likely to come through formal stock exchange channels.

Conclusion

Bharat Immunologicals was trading around ₹15 in mid-September 2026 as reports said the Union Cabinet cleared a proposal to shut down BIBCOL, a PSU manufacturer that stopped OPV production in late 2022. The next clarity point will be any formal filings or official communication that details process and timelines.